Comprehensive Study of Social Representation of Platelet Transfusion in Patients Followed for Advanced Hematological Malignancies (R-PLQ)

NCT03806712 | Completed

• 1 other identifier: P/2019/413
• Study Type: observational
• Target: 45
• Locations: 1 country
• Sites: 1

Brief Summary

Limited data is available for end of life care in hematologic malignancies, moreover with thrombocytopenic patients. Thrombopenia is a frequent complication, specific of bone marrow involvement in those diseases or its treatments. Yet, a few studies was interested in, whereas platelet transfusion is the only treatment indicated. As it represent a scarce, limited resource, the ethical principles are in conflict in this setting and there's a lack of recommendation. The final decision is take by the clinician and his patient, but no study exist in representation of the two parts. We provide a qualitative study to understand what this decision is made of.

Conditions

Platelet Transfusion; Hematological Malignancy; Palliative Care

Keywords

social representation

Outcome Measures

Primary Outcomes (1)

• measure the impact of social representation on platelet transfusion practice

  inner core and peripheral items of platelet transfusion of each participant will be collected until reaching saturation, it's to say that the repetition of some terms will be measured between each interview thank's to a questionnaire of at least two principals opened questions.

  3 months

Study Arms (3)

patient

patient with advanced, non curative hematological malignancies multi method questionary, at least 1 hour per patient

Other: multi method questionary (developped by De Rosa, in 1995 and 2014)

hematologist

medical practitioner of platelet transfusion multi method questionary, at least 1 hour per hematologist

Other: multi method questionary (developped by De Rosa, in 1995 and 2014)

Nurses

nurses working in hematology, practicing platelet transfusion multi method questionary, at least 1 hour per nurse

Other: multi method questionary (developped by De Rosa, in 1995 and 2014)

Interventions

multi method questionary (developped by De Rosa, in 1995 and 2014) OTHER

questions from an association network according to the subject and the grounded theorise (Glasser and Strauss)

Nurses; hematologist; patient

Eligibility Criteria

• Age: 18 Years - 100 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patient with advanced hematological malignancies, transfused in platelet regulary, hematologist's nurses who practice platelet transfusion and hematologist who prescribe the transfusion.

You may qualify if:

• major patient
• patient with advanced hematological malignancies
• patient transfused in platelet regularly (3 time at least in last month)
• medical practioner, hematologist, prescribing platelet transfusion at least one per week.
• nurse working in hematology, practicing platelet transfusion at lest one peer week.

You may not qualify if:

• minor patient
• non communicant patient
• non transfused platelet patient
• non voluntary patient or hematologist or nurses
• non graduated hematologist

Sponsors & Collaborators

• Centre Hospitalier Universitaire de Besancon: lead

Study Sites (1)

Moracchini

Besançon, 25000, France

Location

Related Publications (3)

• McGrath P, Leahy M. Catastrophic bleeds during end-of-life care in haematology: controversies from Australian research. Support Care Cancer. 2009 May;17(5):527-37. doi: 10.1007/s00520-008-0506-1. Epub 2008 Sep 23.

  PMID: 18810505 BACKGROUND

• McGrath P, Holewa H. Special considerations for haematology patients in relation to end-of-life care: Australian findings. Eur J Cancer Care (Engl). 2007 Mar;16(2):164-71. doi: 10.1111/j.1365-2354.2006.00745.x.

  PMID: 17371426 BACKGROUND

• Jeoffrion C, Dupont P, Tripodi D, Roland-Levy C. [Social representations of illness: Comparison of "expert" knowledge and "naive" knowledge]. Encephale. 2016 Jun;42(3):226-33. doi: 10.1016/j.encep.2015.12.007. Epub 2016 Jan 12. French.

  PMID: 26796561 BACKGROUND

MeSH Terms

Conditions

Hematologic Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Hematologic Diseases; Hemic and Lymphatic Diseases

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 30, 2018
• First Posted: January 16, 2019
• Study Start: April 1, 2019
• Primary Completion: June 1, 2019
• Study Completion: July 22, 2019
• Last Updated: July 25, 2019

Record last verified: 2019-07

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)